EUVIMEDEUVIMED entdecken
CrossrefInfokarte

THE EFFECT OF CARBOPLATIN CHEMOTHERAPY REGULATION ON HEARING FUNCTIONS IN PATIENTS OF NASOPHARYNGEAL CARCINOMA

Ita Wahyuni, Denny S Utama, Abla Ghanie

INTERNATIONAL JOURNAL OF NASOPHARYNGEAL CARCINOMA (IJNPC) · 2019

DOI: 10.32734/ijnpc.v1i2.1149 ↗
AbstractBibliografische Angaben

Abstract

Introduction: The incidence of hearing loss after treatment with carboplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients were evaluated, and relationships of loss with host factors, treatment-related factors were investigated. Objective: To evaluate the effect of giving a carboplatin chemotherapy regimen for 6 times chemotherapy (serial chemotherapy) on hearing function in patients with nasopharyngeal carcinoma. The incidence of hearing loss after treatment with carboplatin-based chemotherapy in nasopharyngeal carcinoma (NPC) patients were evaluated, and relationships of loss with host factors, treatment-related factors were investigated. Method: Thirty NPC patients were treated with carboplatin chemotherapy from 2015 to 2017 were analyzed. Pure tone audiometry and Distortion Product of Otoacoustic emission (DPOAE) were performed during the follow-up period, with a median time of 36 months, ranging from 24 to 36 months. Correlation of SNHL at frequencies (pure tone average, 0.5-8 kHz) with a series of factors was analyzed. Results: Among 30 participant (60 ears), using the Wilcoxon test, the mean threshold after series III was significant (p=0,000) and the mean of after series VI and significant (p= 0,000). The relationship between DPOAE results and pure tone audiometry was also carried out in the early stages of series III. Kaplan Meier's survival analysis improvement from post-III series (6 weeks) of participants who survived as many as 23 participants (76.67%) and in the post-chemotherapy evaluation of VI series (15 weeks) participants who survived as many as 8 participants. Bivariate statistical analysis using the Spearman non-parametric correlation test, there was a significant relationship between the mean dose and the decrease in the hearing threshold. p=0.00 (

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →